A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease with limited symptomatic treatment options. Aggregation of α‐synuclein in oligodendrocytes is believed to be a central mechanism of the neurodegenerative process. PD01A and PD03A are 2 novel therapeutic vaccine candidates co...

Descripción completa

Detalles Bibliográficos
Autores principales: Meissner, Wassilios G., Traon, Anne Pavy‐Le, Foubert‐Samier, Alexandra, Galabova, Gergana, Galitzky, Monique, Kutzelnigg, Alexandra, Laurens, Brice, Lührs, Petra, Medori, Rossella, Péran, Patrice, Sabatini, Umberto, Vergnet, Sylvain, Volc, Dieter, Poewe, Werner, Schneeberger, Achim, Staffler, Günther, Rascol, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754431/
https://www.ncbi.nlm.nih.gov/pubmed/32882100
http://dx.doi.org/10.1002/mds.28218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754431/
https://www.ncbi.nlm.nih.gov/pubmed/32882100
http://dx.doi.org/10.1002/mds.28218

Ejemplares similares